{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83e\ude7a Beyond Diabetes, Beyond Albuminuria, Beyond Expectations: Finerenone Across the CKD Spectrum","description":"\ud83d\ude80 Major advance in nephrology and cardiorenal medicine! &amp;nbsp; The INFINITY pooled analysis (14,574 participants) demonstrates that finerenone reduces CKD progression, kidney failure, heart failure hospitalization, cardiovascular death, and even all-cause mortality across a broad spectrum of chronic kidney disease\u2014not just type 2 diabetes. \ud83e\ude7a\u2764\ufe0f\ud83e\ude7a &amp;nbsp; Benefits were remarkably consistent across glycemic status, CKD etiology, eGFR, albuminuria, and SGLT2 inhibitor use. Hyperkalemia remains the key safety consideration but serious events were uncommon. &amp;nbsp; Could finerenone become a foundational therapy for CKD regardless of diabetes status? \ud83d\udd2c\ud83d\udcc8 &amp;nbsp; #CKD #Nephrology #Cardiology #Finerenone #CardioRenal #MedicalPodcasts #INFINITYTrial #KidneyDisease #HeartFailure #PrecisionMedicine ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41641675\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202954265"}